Get started
Author

W. Robert Simons

Observed names: W R Simons, W Robert Simons, W Simons, W. R. Simons, W.R. Simons, W.Robert Simons
OpenAlex ID: A5113535339
Variations in compliance among hypertensive patients by drug class: implications for health care costs
1997 · John A. Rizzo, W. Robert Simons · Clinical Therapeutics · 173
A population-based European cohort study of persistence in newly diagnosed hypertensive patients
2002 · J Hasford, A Mimran, et al. · Journal of Human Hypertension · 109
The Cost of Relapse in Schizophrenia and Schizoaffective Disorder
2009 · Paul Fitzgerald, Anthony de Castella, et al. · Australasian Psychiatry · 22
Comparative Cost Effectiveness of Angiotensin II Receptor Blockers in a US Managed Care Setting
2003 · W. Robert Simons · PharmacoEconomics · 21
Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer
2003 · W.Robert Simons, David Jones, et al. · Clinical Therapeutics · 20
The Economic Consequences of Rheumatoid Arthritis
2012 · W. Robert Simons, Lisa C. Rosenblatt, et al. · Journal of Occupational and Environmental Medicine · 19
Cost-Benefit Model Comparing Two Alternative Immunisation Programmes Against Serogroup C Meningococcal Disease
2003 · Carol Rancourt, Jean-Pierre Gr??goire, et al. · PharmacoEconomics · 14
Comparative Effectiveness of Dalteparin and Enoxaparin in a Hospital Setting
2011 · William Carson, Blane Schilling, et al. · Journal of Pharmacy Practice · 6
Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: A phase III, open-label, randomized study.
2013 · Javier Cortes, Ahmad Awada, et al. · Journal of Clinical Oncology · 5
An Economic Evaluation of Colesevelam when Added to Metformin-, Insulin- or Sulfonylurea-Based Therapies in Patients with Uncontrolled Type 2 Diabetes Mellitus
2010 · W. Robert Simons, Michael A. Hagan · PharmacoEconomics · 5
The costs and effects of switching calcium channel blockers: evidence from Medicaid claims data
1995 · W. Robert Simons, John A. Rizzo, et al. · Clinical Therapeutics · 5
Abstract P1-12-08: Quality of Life in Patients with Locally Advanced or Metastatic Breast Cancer Previously Treated with Anthracyclines and Taxanes who Received Eribulin Mesylate or Capecitabine in a Phase III, Open-label, Randomized Study
2012 · Javier Cortes, Ahmad Awada, et al. · Cancer Research · 4
A real-world evaluation of the effectiveness of dalteparin in the prevention of recurrent venous thromboembolism compared to warfarin in patients with cancer.
2010 · W. R. Simons, Y. Choe, et al. · Journal of Clinical Oncology · 4
Content validity of signs and symptoms measures with the EORTC core module in women with locally advanced or metastatic breast cancer (MBC): A phase II trial with eribulin mesylate.
2013 · W. Robert Simons · Journal of Clinical Oncology · 3
Health economics and outcomes research with retrospective data.
1995 · W R Simons, M E Smith · PubMed · 3
The economic assessment of eribulin compared to treatment of physician's choice (TPC) in Australia.
2013 · Trefor Jones, W. Robert Simons · Journal of Clinical Oncology · 2
Quality of life (QoL) and content validity in objective tumor response.
2013 · Christopher Twelves, Ahmad Awada, et al. · Journal of Clinical Oncology · 1
Ds4 Burden of Proof…proof of Principle: Replication Quantification, Replication and Validation… Standards of Evidence in Outcomes Research Surrogate Endpoints for All-cause Mortality
2011 · W.R. Simons · Value in Health · 1
Comparative Cost for Required Monitoring to Detect Adverse Events or Laboratory Abnormalities: Dasatinib Versus Nilotinib.
2009 · W. Robert Simons, Ross Maclean, et al. · Blood · 1
Health State Utility Determination in Advanced Stage Breast Cancer Patients
2012 · W.R. Simons · Annals of Oncology
Health economic assessments of anticancer agents: A comparison of assessment technologies applied to end-stage cancer.
2011 · S. Kobina, W. R. Simons · Journal of Clinical Oncology
Pcv77 Cost Effectiveness Analysis the Prevention of Venous Thromboembolism in Immobilized Patients (prevent) Trial: Thromboprophylactic Treatment With Dalteparin Versus Placebo in Acutely Ill Patients
2010 · A Powers, E Kim, et al. · Value in Health
PDF
Economics of persistence with initially prescribed antipsychotic in patients with psychosis or bipolar disorder
2003 · R.E. White, W.R. Simons, et al. · Schizophrenia Research
Cost-Benefit Model Comparing Two Alternative Immunisation Programmes Against Serogroup C
2003 · Carol Rancourt, Jean-Pierre Gr, et al.
Works count: 24
Citation count: 418
H-index: 7
I10-index: 7
Year
Topic
Type